ArticleScientific reports2026
A reaction-based fluorescence for monitoring β-Gal in living cells and BALB/c nude mice.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
β-Galactosidase (β-Gal), as a key biomarker closely associated with colorectal cancer, holds an indispensable position in the early diagnosis and therapeutic efficacy assessment of cancer. MQ-βGal achieves highly specific targeted binding with β-Gal and demonstrates outstanding comprehensive performance, featuring a broad linear response range, high detection sensitivity and robust interference resistance. Benefiting from MQ-βGal's favorable biocompatibility and low cytotoxicity, it has been successfully applied to real-time tracking of dynamic β-Gal activity changes within living cell. Building upon this, MQ-βGal's application has been further extended to the in vivo level, successfully achieving in situ monitoring of endogenous β-Gal activity in BALB/c nude mouse models, thereby validating its suitability for in vivo biological imaging. More significantly, clinical sample validation experiments demonstrate that MQ-βGal effectively distinguishes biological samples from healthy individuals and colorectal cancer patients, specifically identifying abnormal β-Gal expression patterns during colorectal cancer development. These findings fully highlight the potential application value and translational prospects of this fluorescent diagnostic system in the early clinical diagnosis and disease assessment of colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.